亿帆医药(002019.SZ)：前三季度净利润3.88亿元 同比增加5.84%

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) reported a slight increase in revenue and net profit for the first three quarters of 2025, indicating stable performance in a challenging market environment [1] Financial Performance - The company achieved an operating revenue of 3.923 billion yuan, representing a year-on-year increase of 1.67% [1] - The net profit attributable to shareholders reached 388 million yuan, reflecting a year-on-year increase of 5.84% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 315 million yuan, showing a significant year-on-year increase of 25.17% [1] - Basic earnings per share stood at 0.32 yuan [1]